| Identification | Back Directory | [Name]
NTFAPI | [CAS]
2374782-03-1 | [Synonyms]
NTFAPI
GFA-1002
NOTA-FAPI-4
(S)-2,2’-[7-[2-[4-[3-[[4-[[2-(2-Cyano-4,4-difluoro-1-pyrrolidinyl)-2-oxoethyl]carbamoyl]-6-quinolyl]oxy]propyl]-1-piperazinyl]-2-oxoethyl]-1,4,7-triazonane-1,4-diyl]diacetic Acid
(S)-2,2'-(7-(2-(4-(3-((4-((2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)piperazin-1-yl)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid | [Molecular Formula]
C36H47F2N9O8 | [MDL Number]
MFCD33029295 | [MOL File]
2374782-03-1.mol | [Molecular Weight]
771.82 |
| Chemical Properties | Back Directory | [Boiling point ]
1061.8±65.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.82±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality[1][2][3]. | [in vivo]
18F-AlF-NOTA-FAPI PET/CT showa more metastatic lesions that has more increased activity than 18F-FDG PET/CT[3].
| [IC 50]
RDC Bifunctional Chelator | [References]
[1] Wang S, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4259-4271. DOI:10.1007/s00259-021-05470-5
[2] Guo YH, et al. Comparison of 18F-AlF-NOTA-FAPI and 18F-FDG Imaging in a Patient With Gastric Signet-Ring Cell Carcinoma. Clin Nucl Med. 2021 Nov 1;46(11):929-930. DOI:10.1097/RLU.0000000000003742
[3] Ge L, et al. Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4025-4036. DOI:10.1007/s00259-022-05836-3 |
|
| Company Name: |
Tetranov Biopharm
|
| Tel: |
13526569071 |
| Website: |
http://www.leadmedpharm.com/index.html |
|